Prognostic Factors and Second-Line Treatment Options in ES-SCLC

A panelist discusses how early relapse within 6 months of platinum-based therapy signals poor prognosis and limited treatment sensitivity. They weigh second-line treatment options, including newer agents such as tarlatamab, against traditional chemotherapy, noting how performance status and comorbidities influence treatment choice.

A panelist discusses how molecular profiling, prior response depth, and time-to-relapse remain critical prognostic tools. They explain that these clinical parameters help guide whether patients are suitable for active therapy vs supportive care.

A panelist discusses how advances in bispecific therapies are redefining treatment paradigms by offering improved survival and safety compared with historical chemotherapeutic options.